Culture System for Isolating Circulating Tumor cells_2
Overview
This culture system utilizes the special affinity difference of biomedical material coating for different cells to achieve the effect of isolating tumor cells from the blood sample. The coating of the system has the characteristic that to make the WBCs adhesion, but the cancer cells in the blood sample suspend in the culture medium, which achieves the effect of separating cancer cells from the blood. The supernatant with the cancer cells can further be isolated from the cultural system for related analysis and detection to achieve early diagnosis and screening.
Full Title of Study: “Culture System for Isolating Circulating Tumor Cells”
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Other
- Study Primary Completion Date: August 31, 2020
Clinical Trial Outcome Measures
Primary Measures
- The Number of Circulating Cancer Cells from The Blood Sample
- Time Frame: about 1 week
- The number of circulating cancer cells from the blood sample will be investigated. To distinguish cancer cells from blood cells for the system, the lung cancer cells were immunofluorescence stained for Cytokeratin, white blood cells were stained for CD45 and nuclei were counterstained with DAPI.
Secondary Measures
- Cancer Cell Isolation Efficiency of The Isolation System
- Time Frame: about 1 week
- The cell isolation efficiency was characterized by spiking A549 lung cancer cells with celltracker at the concentrations 1000, 100 and 10 cells into whole blood.
Participating in This Clinical Trial
Inclusion Criteria
- Patients with lung cancer are between the ages of 20 and 70 – Willing to sign the consent form under the informed consent Exclusion Criteria:
- Vulnerable Subjects included minors, prisoners, aborigines, pregnant women, people with mental disorders, students, and subordinates, etc.
Gender Eligibility: All
Minimum Age: 20 Years
Maximum Age: 70 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- National Taiwan University Hospital
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- Tai-Horng Young, Study Chair, Institute of Biomedical Engineering, National Taiwan University
- Overall Contact(s)
- Tai-Horng Young, 886-2-23123456, thyoung@ntu.edu.tw
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.